The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened by Federal Chairman Jerome Powell’s bearish comments on the US economy, saying that the US’ tariff policies could drive up inflation and “move us further away from our goals.” The tech-heavy Nasdaq dropped the hardest, down 3.07 percent. The S&P 500 declined by 2.24 percent, and the Dow Jones was down by 1.73 percent. To come up with the list of the stocks that declined on Wednesday, we only considered the stocks with $2 billion market capitalization and $5 million trading volume.Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. ImmunityBio, Inc. (NASDAQ:IBRX) ImmunityBio, Inc. (NASDAQ:IBRX) declined for a second consecutive day on Wednesday, shedding 10.79 percent to close at $2.48 apiece as investors sold off positions amid the broader market decline. In recent news, ImmunityBio, Inc. (NASDAQ:IBRX) announced that it has completed multiple submissions to the Food and Drug Administration, including a supplemental biologic license application for its novel immunotherapy Anktiva, which aims to treat unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS). The company is also underway with the global expansion of Anktiva. Just recently, it submitted a marketing authorization request to the European Medicines Agency for the review and assessment of the therapy. If approved by the EMA, ImmunityBio, Inc. (NASDAQ:IBRX) would be able to sell ANKTIVA in 27 countries in Europe, including Norway, Iceland, and Liechtenstein. Overall IBRX ranks 2nd on our list of the stocks that declined on Wednesday. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. View Comments
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...